Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...
Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback